Bell Investment Advisors’s Corcept Therapeutics CORT Stock Holding History

Bell Investment Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.43K	Hold	74	–	–	﹤0.01%	876
2026 Q1	$2.98K	Sell	74 -32	-30%	-$1.2K	﹤0.01%	1175
2025 Q4	$3.69K	Buy	106 +7	+7%	+$550	﹤0.01%	1107
2025 Q3	$8.23K	Sell	99 -71	-42%	-$5.14K	﹤0.01%	705
2025 Q2	$12.5K	Buy	170 +21	+14%	+$1.52K	﹤0.01%	594
2025 Q1	$17K	Hold	149	–	–	﹤0.01%	432
2024 Q4	$7.51K	Buy	149 +28	+23%	+$1.47K	﹤0.01%	724
2024 Q3	$5.6K	Hold	121	–	–	﹤0.01%	875
2024 Q2	$3.93K	Buy	121 +50	+70%	+$1.37K	﹤0.01%	1043
2024 Q1	$1.79K	Hold	71	–	–	﹤0.01%	1404
2023 Q4	$2.31K	Hold	71	–	–	﹤0.01%	1267
2023 Q3	$1.94K	Hold	71	–	–	﹤0.01%	1287
2023 Q2	$1.58K	Hold	71	–	–	﹤0.01%	1408
2023 Q1	$1.54K	Buy	71 +23	+48%	+$504	﹤0.01%	1394
2022 Q4	$975	Buy	48 +1	+2%	+$25	﹤0.01%	1609
2022 Q3	$1K	Hold	47	–	–	﹤0.01%	1359
2022 Q2	$1K	Buy	+47	New	+$1.02K	﹤0.01%	1380
2021 Q4	$1K	Sell	48 -20	-29%	-$406	﹤0.01%	1390
2021 Q3	$1K	Buy	+68	New	+$1.42K	﹤0.01%	1320

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bell Investment Advisors's CORT Position: Q2 2026 in Review

Bell Investment Advisors held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 74 shares worth $6.43K. The position accounts for ﹤0.01% of the portfolio, ranked #876.

Bell Investment Advisors first reported a position in CORT in Q3 2021 and has held it in 19 quarters since. The position peaked at $17K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Bell Investment Advisors held 74 shares of Corcept Therapeutics worth $6.43K as of Q2 2026.
Bell Investment Advisors left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #876 holding.
Bell Investment Advisors first reported a position in Corcept Therapeutics in Q3 2021 and has held it in 19 quarters since.
Bell Investment Advisors's Corcept Therapeutics position peaked at $17K in Q1 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.